The Truong lab uses principles from synthetic and systems biology, cell fate reprogramming, epigenetics, and immunology. He and his team “rewrite” the human genome in induced pluripotent stem cells (iPSCs) to build cell therapies and regenerative medicine. The group is developing an off-the-shelf chassis iPSC that can be given to any person without immune rejection. This chassis iPSC will enable large-scale restructuring of the human genome, introduction of large and more sophisticated genetic circuits for cell programming, and the production of any somatic cell for living therapies. The group currently focuses on developing programmable off-the-shelf Dendritic Cells from human iPSCs as an immunotherapy platform.